^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MLL rearrangement

    i
    Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
    Apply
    Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (NCT06013423)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    07/06/2024
    Primary completion :
    10/31/2024
    Completion :
    10/31/2025
    KMT2A • HLA-DRB1 • HLA-B
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (NCT01860937)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    05/01/2013
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    KMT2A • IKZF1
    |
    MLL rearrangement • IKZF1 deletion
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene (NCT05886049)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    11/10/2024
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    FLT3 • NPM1 • KMT2A
    |
    FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL rearrangement • FLT3 wild-type • MLL mutation
    |
    daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)
    Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06001788)
    Phase 1
    Kura Oncology, Inc.
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    02/22/2024
    Primary completion :
    08/01/2026
    Completion :
    08/01/2027
    FLT3 • NPM1 • KMT2A
    |
    FLT3 mutation • NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
    |
    cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • ziftomenib (KO-539) • fludarabine IV
    Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (AALL1621) (NCT02981628)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    06/19/2017
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    KMT2A • CD22
    |
    MLL rearrangement • CD22 expression
    |
    cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies (NCT02443831)
    Phase 1
    University College, London
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    04/01/2016
    Primary completion :
    12/31/2028
    Completion :
    12/31/2036
    ABL1 • BCR • KMT2A • IGH • CD22 • TCF3
    |
    KMT2A rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous
    A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance (NCT03114865)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    05/27/2024
    Initiation :
    09/05/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    KMT2A
    |
    MLL rearrangement
    |
    Blincyto (blinatumomab) • dexamethasone
    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (AALL1131) (NCT02883049)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    02/29/2012
    Primary completion :
    12/31/2022
    Completion :
    09/22/2024
    ABL1 • BCR • RUNX1 • KMT2A • ETV6
    |
    MLL rearrangement • MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (NCT04644016)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/24/2024
    Initiation :
    11/20/2020
    Primary completion :
    12/20/2025
    Completion :
    12/20/2025
    KMT2A
    |
    MLL rearrangement • MLL rearrangement
    |
    clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion
    Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse (NCT01995578)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    05/22/2024
    Initiation :
    12/01/2013
    Primary completion :
    09/27/2023
    Completion :
    09/27/2023
    FLT3 • KMT2A
    |
    FLT3 mutation • MLL rearrangement
    |
    azacitidine
    A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) (NCT04065399)
    Phase 1/2
    Syndax Pharmaceuticals
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/05/2019
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    KMT2A • NUP98
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement
    |
    Revuforj (revumenib) • Tybost (cobicistat)
    A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516)
    Phase 1
    Syndax Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    03/09/2022
    Primary completion :
    05/01/2024
    Completion :
    06/01/2024
    KMT2A • NUP98
    |
    KMT2A rearrangement • MLL rearrangement
    |
    cytarabine • cyclophosphamide • Revuforj (revumenib)
    A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML (KOMET-007) (NCT05735184)
    Phase 1
    Kura Oncology, Inc.
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    07/18/2023
    Primary completion :
    05/01/2026
    Completion :
    05/01/2027
    NPM1 • KMT2A
    |
    NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
    |
    Venclexta (venetoclax) • azacitidine • daunorubicin • ziftomenib (KO-539)
    Allo HSCT Using RIC and PTCy for Hematological Diseases (NCT05805605)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    05/01/2023
    Primary completion :
    10/22/2027
    Completion :
    10/22/2028
    NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV
    Cord Blood Transplant in Adults With Blood Cancers (NCT05884333)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/02/2024
    Initiation :
    05/22/2023
    Primary completion :
    05/22/2028
    Completion :
    05/22/2028
    KMT2A
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide
    A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to (EU PIP Study) (NCT05748171)
    Phase 2
    Pfizer
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    05/17/2023
    Primary completion :
    07/11/2028
    Completion :
    07/09/2031
    TP53 • KMT2A • CD22 • TCF3 • PBX1
    |
    KMT2A rearrangement • MLL rearrangement • CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (APAL2020SC) (NCT04726241)
    Phase 1/2
    LLS PedAL Initiative, LLC
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    04/18/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    KMT2A
    |
    KMT2A rearrangement • MLL rearrangement
    A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (NCT05761171)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    01/08/2024
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    KMT2A
    |
    MLL rearrangement
    |
    cytarabine • methotrexate • vincristine • Revuforj (revumenib) • Oncaspar liquid (pegaspargase) • fludarabine IV • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)
    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    03/30/2018
    Primary completion :
    01/10/2025
    Completion :
    11/10/2025
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide
    Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    04/10/2024
    Initiation :
    01/02/2019
    Primary completion :
    06/23/2020
    Completion :
    06/28/2024
    FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA
    |
    FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)
    Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT04659616)
    Phase 1
    OHSU Knight Cancer Institute
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    01/14/2021
    Primary completion :
    08/01/2025
    Completion :
    02/01/2026
    TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation
    |
    cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)
    Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (NCT05327894)
    Phase 3
    Princess Maxima Center for Pediatric Oncology
    Recruiting
    Last update posted :
    04/05/2024
    Initiation :
    12/15/2022
    Primary completion :
    09/01/2027
    Completion :
    09/01/2030
    KMT2A
    |
    KMT2A rearrangement • MLL rearrangement
    |
    Blincyto (blinatumomab)
    Venetoclax Basket Trial for High Risk Hematologic Malignancies (NCT05292664)
    Phase 1
    Andrew E. Place, MD
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    03/29/2023
    Primary completion :
    04/02/2025
    Completion :
    04/02/2027
    FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1
    |
    KMT2A rearrangement • MLL rearrangement • IKZF1 deletion • ABL1 fusion • ABL1 deletion
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane
    A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (NCT01684150)
    Phase 1
    Epizyme, Inc.
    Completed
    Last update posted :
    03/26/2024
    Initiation :
    09/01/2012
    Primary completion :
    11/01/2015
    Completion :
    02/01/2016
    KMT2A
    |
    MLL rearrangement
    |
    pinometostat (EPZ-5676)
    Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (AALL15P1) (NCT02828358)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/25/2024
    Initiation :
    04/01/2017
    Primary completion :
    09/30/2020
    Completion :
    09/22/2024
    KMT2A
    |
    KMT2A rearrangement • MLL rearrangement
    |
    cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (NCT04307576)
    Phase 3
    Mats Heyman
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2027
    Completion :
    06/30/2032
    MYC • BCL2 • KMT2A
    |
    MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement
    |
    imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine
    Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (NCT01203722)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    09/01/2010
    Primary completion :
    09/01/2025
    Completion :
    12/01/2025
    FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)
    |
    cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
    Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies (NCT05011422)
    Phase 1
    Washington University School of Medicine
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    11/03/2022
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10
    |
    MLL rearrangement • NUP98 rearrangement
    Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT04262843)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    02/07/2020
    Primary completion :
    08/04/2025
    Completion :
    08/04/2025
    FLT3 • CD8 • HLA-DRB1 • CD4 • NCAM1
    |
    MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation (NCT03434730)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    03/04/2024
    Initiation :
    02/07/2018
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    KMT2A
    |
    MLL rearrangement • MLL rearrangement
    |
    Actemra IV (tocilizumab) • cyclosporine • Neupogen (filgrastim)
    Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03494569)
    Phase 1
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    07/06/2018
    Primary completion :
    11/11/2028
    Completion :
    11/11/2028
    FLT3 • NPM1 • HLA-DRB1 • HLA-B • HLA-C
    |
    MLL rearrangement
    |
    melphalan • fludarabine IV
    A Study of BN104 in the Treatment of Acute Leukemia (NCT06052813)
    Phase 1/2
    BioNova Pharmaceuticals (Shanghai) LTD.
    Recruiting
    Last update posted :
    02/21/2024
    Initiation :
    09/16/2023
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    NPM1 • KMT2A
    |
    NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
    Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) (NCT05507827)
    Phase 1
    Dr. Melody Smith, MD, MS
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    08/18/2022
    Primary completion :
    01/01/2037
    Completion :
    01/01/2037
    CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C
    |
    KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement
    |
    Orca-T • firicabtagene autoleucel (CRG-022)
    Off-the-shelf NK Cells + SCT for Myeloid Malignancies (NCT05115630)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/16/2024
    Initiation :
    04/08/2022
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
    90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT05139004)
    Phase 1
    City of Hope Medical Center
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    07/19/2022
    Primary completion :
    12/13/2024
    Completion :
    12/13/2024
    FLT3 • NPM1 • IL2RA • ISG20
    |
    MLL rearrangement • IL2RA expression • Chr t(9;11)
    |
    melphalan • fludarabine IV • Kepivance (palifermin) • Simulect (basiliximab)
    Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (NCT03613532)
    Phase 1
    Jacqueline Garcia, MD
    Recruiting
    Last update posted :
    01/26/2024
    Initiation :
    10/24/2018
    Primary completion :
    02/01/2025
    Completion :
    02/01/2026
    KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2
    |
    TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type
    |
    Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan
    Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia (NCT00357565)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    01/26/2024
    Initiation :
    11/01/2005
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    KMT2A
    |
    MLL rearrangement • MLL rearrangement
    |
    melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim)
    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia (V2-MA-1801) (NCT03826992)
    Phase 1
    Children's Hospital Medical Center, Cincinnati
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    12/27/2018
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    KMT2A
    |
    MLL rearrangement
    |
    Venclexta (venetoclax) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy (NCT05009719)
    Phase 1/2
    St. Petersburg State Pavlov Medical University
    Active, not recruiting
    Last update posted :
    01/04/2024
    Initiation :
    04/01/2021
    Primary completion :
    04/01/2023
    Completion :
    04/01/2024
    TP53 • FLT3 • KMT2A • NUP98
    |
    TP53 mutation • MLL rearrangement
    Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT02446964)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/03/2024
    Initiation :
    06/25/2015
    Primary completion :
    06/15/2024
    Completion :
    06/15/2024
    FLT3 • HLA-DRB1
    |
    MLL rearrangement • Chr t(9;11)
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Orphan Indications for CD19 Redirected Autologous T Cells (NCT04276870)
    Phase 2
    Stephan Grupp MD PhD
    Recruiting
    Last update posted :
    12/19/2023
    Initiation :
    03/12/2020
    Primary completion :
    03/10/2028
    Completion :
    03/10/2037
    CD19 • KMT2A
    |
    MLL rearrangement • CD19 expression
    |
    Kymriah (tisagenlecleucel-T)
    Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells (NCT01092026)
    Phase N/A
    Universitair Ziekenhuis Brussel
    Completed
    Last update posted :
    12/06/2023
    Initiation :
    11/01/2010
    Primary completion :
    09/01/2018
    Completion :
    09/01/2018
    FLT3 • KMT2A
    |
    MLL rearrangement • MLL rearrangement